⁹⁹ᵐTc-maraciclatide Granted FDA Fast Track Designation for the Visualization of Inflammation in Interstitial Lung Disease 

Serac Healthcare Limited announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation to ^99mTc-maraciclatide as a diagnostic SPECT-CT agent for the “visualization of inflammation in the lungs of patients with known and suspected interstitial lung disease (ILD).”